Companies Enliven Therapeutics, Inc.
Enliven Therapeutics CEO salary & total pay, FY2025: $11.9M
Enliven Therapeutics (ELVN) CEO salary, fiscal 2025: Richard Fair was paid a salary of $38,077 and $11,918,926 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Enliven Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Richard Fair's complete compensation dossier
A PDF and a CSV sent to your email: Richard Fair's pay in every fiscal year Enliven Therapeutics, Inc. reported it, line by line, with Richard Fair's equity grants and Enliven Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $8,279,751FY2023
- $5,461,660FY2024
- $11,918,926FY2025
CEO total pay was $11,918,926 in fiscal 2025 (Richard Fair), up from $5,461,660 in fiscal 2024 (Sam Kintz, the CEO that year).
FY2025: salary $38,077 · bonus $0 · stock awards $0 · option awards $11,880,138
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Fair | $38,077 | $0 | $0 | $11,880,138 | $0 | $0 | $711 | $11,918,926 |
| President and Chief Executive Officer | ||||||||
| Sam Kintz | 624,154 | 0 | 0 | 7,952,553 | 316,800 | 0 | 15,140 | 8,908,647 |
| Former President and Chief Executive Officer | ||||||||
| Helen Collins | 523,000 | 0 | 0 | 2,775,279 | 188,280 | 0 | 15,140 | 3,501,699 |
| Chief Medical Officer | ||||||||
| Ben Hohl | 480,000 | 0 | 0 | 2,775,279 | 172,800 | 0 | 15,094 | 3,443,173 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Fair | $11,918,926 | — | — | — |
| Sam Kintz | 8,908,647 | 5,461,660 | 8,279,751 | ↑ +3,446,987 |
| Helen Collins | 3,501,699 | 2,771,410 | 4,064,839 | ↑ +730,289 |
| Ben Hohl | 3,443,173 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company provides cash incentive compensation to its named executive officers based on their meeting of one or more corporate performance objectives, with the board selecting challenging goals that are achievable only by strong performance. The compensation committee reviews CEO recommendations and market data to determine total compensation, focusing on company results, individual contribution, and goal achievement.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Ben Hohl | Option | 145,916 | 60,084 | 22.75 | — |
| Ben Hohl | Option | 84,791 | 100,209 | 14.85 | — |
| Ben Hohl | Option | — | 171,000 | 22.47 | — |
| Ben Hohl | Option | 92,056 | — | 2.48 | — |
| Helen Collins | Option | 145,916 | 60,084 | 22.75 | — |
| Helen Collins | Option | 84,791 | 100,209 | 14.85 | — |
| Helen Collins | Option | — | 171,000 | 22.47 | — |
| Helen Collins | Option | 266,268 | — | 2.48 | — |
| Richard Fair | Option | — | 875,000 | 18.77 | — |
| Sam Kintz | Option | 188,841 | — | 1.12 | — |
| Sam Kintz | Option | 404,363 | — | 2.48 | — |
| Sam Kintz | Option | 320,166 | — | 22.75 | — |
| Sam Kintz | Option | 187,916 | — | 14.85 | — |
| Sam Kintz | Option | 122,500 | — | 22.47 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard Heyman, Ph.DIndependent · Board Chair · Compensation · Not standing for re-election | $46,000 | — | $365,000 | — | — | $411,000 |
| Jake Bauer, M.B.AIndependent · Audit (Chair) · Compensation | 61,000 | — | 324,985 | — | — | 385,985 |
| Andrew PhillipsIndependent | 57,500 | — | 324,985 | — | — | 382,485 |
| Mika Derynck, M.DIndependent · Audit · Nominating and Corporate Governance | 52,500 | — | 324,985 | — | — | 377,485 |
| Rishi Gupta, J.DIndependent · Audit · Compensation (Chair) | 52,000 | — | 324,985 | — | — | 376,985 |
| Rahul Ballal, Ph.DIndependent | 40,000 | — | 324,985 | — | — | 364,985 |
| Lori Kunkel, M.DIndependent · Nominating and Corporate Governance | 45,000 | — | 243,735 | — | — | 288,735 |
| Richard Fair, M.B.AEmployee director | — | — | — | — | — | 0 |
| Scott Garland, M.B.AIndependent · Nominating and Corporate Governance (Chair) · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $325,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $354,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $354,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Enliven Therapeutics as a peer
Companies that benchmark against ELVN
1 company names ELVN as a compensation peer
- Edgewise Therapeutics, Inc.EWTXFY2025
Each company listed discloses ELVN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELVN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Enliven Therapeutics, Inc. | 2025 | Richard Fair | $38,077 | $0 | $11,880,138 | $0 | $11,918,926 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 47,572,153 | 3,093,447 | 21,027 | 93.89% | Passed |
| 2025 | 2025-06-24 | — | — | — | — | — |
| 2024 | 2024-06-18 | — | — | — | — | — |
| 2023 | 2023-06-23 | — | — | — | — | — |
| 2022 | 2022-06-02 | — | — | — | — | — |
| 2021 | 2021-06-29 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 93.89%a |
| 2025 | 2025-06-24 | —b |
| 2024 | 2024-06-18 | —c |
a. Approved under the standard stated in the filing — “The non-binding, advisory vote to approve the compensation of our named executive officers requires the affirmative vote of the holders of a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented by proxy at the Annual Meeting and voting affirmatively or negatively on such matter (i.e., Proposal No. || Abstentions: Abstentions and broker non-votes, if any, will have no effect on the proposal.”.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 5,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 223 | 41 | 9,189 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 1,302 | 40 | 52,402 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 3,475 | 40 | 137,381 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 354 | 36 | 12,680 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 1,867 | 35 | 66,012 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 7,779 | 34 | 266,659 | Common, open-market sale | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-15 | D | 272,322 | 45 | 12,259,936 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-15 | D | 9,086 | 45 | 409,052 | Common, indirect | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 1,133 | 45 | 50,694 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 2,599 | 44 | 114,018 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 1,268 | 43 | 54,305 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 6,018 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 1,238 | 45 | 55,397 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 3,401 | 44 | 149,179 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 1,379 | 43 | 59,001 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | A | 6,018 | 2 | 14,925 | Common | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 46,776 | 45 | 2,104,920 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 787,024 | 45 | 35,715,149 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 1,477 | 45 | 66,465 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 24,846 | 45 | 1,127,511 | Common, indirect | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-07-06 | D | 5,889 | 51 | 299,421 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-07-06 | D | 4,111 | 50 | 205,482 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 63 | 54 | 3,397 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 2,184 | 53 | 116,669 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 2,063 | 52 | 108,085 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 459 | 52 | 23,660 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 231 | 50 | 11,563 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-17 | — | 1,072 | — | — | 1 insider, 1 accrual row | ||
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 123 | 54 | 6,626 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 2,638 | 53 | 140,823 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 2,564 | 52 | 134,143 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 369 | 51 | 18,997 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 324 | 50 | 16,191 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | A | 1,072 | 2 | 2,659 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 20,491 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 23,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 27,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 87,373 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 158,795 | 60 | 9,561,587 | Common, open-market sale | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 20,491 | 22 | 460,433 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 23,364 | 15 | 346,955 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 27,567 | 25 | 696,894 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 87,373 | 2 | 216,685 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 1,100 | 59 | 65,281 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 3,900 | 58 | 227,650 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-08-17 | D | 1,388 | 59 | 82,383 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-08-17 | D | 4,630 | 58 | 270,168 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 240 | 51 | 12,356 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 1,844 | 51 | 93,507 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 2,916 | 50 | 145,891 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 3,982 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 289 | 51 | 14,881 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 2,194 | 51 | 111,270 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 3,535 | 50 | 176,851 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | A | 3,982 | 15 | 59,133 | Common | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | D | 13,000 | 47 | 606,719 | Common, open-market sale | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | A | 13,000 | 15 | 201,110 | Common | Form 4 ↗ |
| Kristine M. Ball | Director | 2026-10-14 | A | 23,394 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | D | 6,018 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | D | 6,018 | 38 | 231,546 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | A | 6,018 | 15 | 89,367 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | D | 5,000 | 38 | 192,342 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | D | 7,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | D | 3,741 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | A | 7,300 | 18 | 133,590 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | A | 3,741 | 1 | 4,190 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 61 | 48 | 2,903 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 4,939 | 47 | 231,300 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 83 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 5,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 223 | 41 | 9,189 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 1,302 | 40 | 52,402 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | D | 3,475 | 40 | 137,381 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-05-18 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 354 | 36 | 12,680 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 1,867 | 35 | 66,012 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-06-05 | D | 7,779 | 34 | 266,659 | Common, open-market sale | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-15 | D | 272,322 | 45 | 12,259,936 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-15 | D | 9,086 | 45 | 409,052 | Common, indirect | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 1,133 | 45 | 50,694 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 2,599 | 44 | 114,018 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | D | 1,268 | 43 | 54,305 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-06-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 6,018 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 1,238 | 45 | 55,397 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 3,401 | 44 | 149,179 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | D | 1,379 | 43 | 59,001 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-06-17 | A | 6,018 | 2 | 14,925 | Common | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 46,776 | 45 | 2,104,920 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 787,024 | 45 | 35,715,149 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 1,477 | 45 | 66,465 | Common, indirect | Form 4 ↗ |
| ORBIMED ADVISORS LLC | Greater-than-10% holder | 2026-06-22 | D | 24,846 | 45 | 1,127,511 | Common, indirect | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-07-06 | D | 5,889 | 51 | 299,421 | Common, open-market sale | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-07-06 | D | 4,111 | 50 | 205,482 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 63 | 54 | 3,397 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 2,184 | 53 | 116,669 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 2,063 | 52 | 108,085 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 459 | 52 | 23,660 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | D | 231 | 50 | 11,563 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-07-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 1,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 123 | 54 | 6,626 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 2,638 | 53 | 140,823 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 2,564 | 52 | 134,143 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 369 | 51 | 18,997 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | D | 324 | 50 | 16,191 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-07-17 | A | 1,072 | 2 | 2,659 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 20,491 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 23,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 27,567 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 87,373 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | D | 158,795 | 60 | 9,561,587 | Common, open-market sale | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 20,491 | 22 | 460,433 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 23,364 | 15 | 346,955 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 27,567 | 25 | 696,894 | Common | Form 4 ↗ |
| Mika K. Derynck | Director | 2026-08-04 | A | 87,373 | 2 | 216,685 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 1,100 | 59 | 65,281 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | D | 3,900 | 58 | 227,650 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-08-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-08-17 | D | 1,388 | 59 | 82,383 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-08-17 | D | 4,630 | 58 | 270,168 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 240 | 51 | 12,356 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 1,844 | 51 | 93,507 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | D | 2,916 | 50 | 145,891 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-09-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 3,982 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 289 | 51 | 14,881 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 2,194 | 51 | 111,270 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | D | 3,535 | 50 | 176,851 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-09-17 | A | 3,982 | 15 | 59,133 | Common | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | D | 13,000 | 47 | 606,719 | Common, open-market sale | Form 4 ↗ |
| J. Scott Garland | Director | 2026-10-01 | A | 13,000 | 15 | 201,110 | Common | Form 4 ↗ |
| Kristine M. Ball | Director | 2026-10-14 | A | 23,394 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | D | 6,018 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | D | 6,018 | 38 | 231,546 | Common, open-market sale | Form 4 ↗ |
| Ben Hohl | Chief Financial Officer | 2026-10-19 | A | 6,018 | 15 | 89,367 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | D | 5,000 | 38 | 192,342 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-10-19 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | D | 7,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | D | 3,741 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | A | 7,300 | 18 | 133,590 | Common | Form 4 ↗ |
| Lori Anne Kunkel | Director | 2026-10-30 | A | 3,741 | 1 | 4,190 | Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 61 | 48 | 2,903 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | D | 4,939 | 47 | 231,300 | Common, open-market sale | Form 4 ↗ |
| Helen Collins | Chief Medical Officer | 2026-11-17 | A | 5,000 | 2 | 12,400 | Common | Form 4 ↗ |
Sources (102 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Fair. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 36. As printed: 11,918,926. View filing ↗
- Section 01, Sam Kintz. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 8,908,647. View filing ↗
- Section 01, Helen Collins. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,501,699. View filing ↗
- Section 01, Ben Hohl. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,443,173. View filing ↗
- Section 08, Richard Heyman, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 411,000. View filing ↗
- Section 08, Jake Bauer, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 385,985. View filing ↗
- Section 08, Andrew Phillips. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 382,485. View filing ↗
- Section 08, Mika Derynck, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 377,485. View filing ↗
- Section 08, Rishi Gupta, J.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 376,985. View filing ↗
- Section 08, Rahul Ballal, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 364,985. View filing ↗
- Section 08, Lori Kunkel, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 288,735. View filing ↗
- Section 08, Richard Fair, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Scott Garland, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristine M. Ball 2026-10-14. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 93.89% (votes for as printed: 47,572,153). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 354,000 + equity 0 + all other 0 = 354,000, summed across the director compensation table rows.
- Enliven Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Enliven Therapeutics, Inc.'s own proxy. As printed: 11,918,926. View filing ↗